273 related articles for article (PubMed ID: 19591808)
41. Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
Marino MJ; Knutsen LJ; Williams M
J Med Chem; 2008 Mar; 51(5):1077-107. PubMed ID: 18198826
[No Abstract] [Full Text] [Related]
42. D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminase.
Wu M; Zhou XJ; Konno R; Wang YX
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1042-6. PubMed ID: 17042912
[TBL] [Abstract][Full Text] [Related]
43. High-Throughput Screening Strategy Identifies Allosteric, Covalent Human D-Amino Acid Oxidase Inhibitor.
Terry-Lorenzo RT; Masuda K; Sugao K; Fang QK; Orsini MA; Sacchi S; Pollegioni L
J Biomol Screen; 2015 Dec; 20(10):1218-31. PubMed ID: 26296926
[TBL] [Abstract][Full Text] [Related]
44. Pharmacologic implications of neurobiological models of schizophrenia.
Goff DC
Harv Rev Psychiatry; 2005; 13(6):352-9. PubMed ID: 16373329
[TBL] [Abstract][Full Text] [Related]
45. Schizophrenia: moving beyond monoamine antagonists.
Conn PJ; Tamminga C; Schoepp DD; Lindsley C
Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
[TBL] [Abstract][Full Text] [Related]
46. Regulating levels of the neuromodulator d-serine in human brain: structural insight into pLG72 and d-amino acid oxidase interaction.
Birolo L; Sacchi S; Smaldone G; Molla G; Leo G; Caldinelli L; Pirone L; Eliometri P; Di Gaetano S; Orefice I; Pedone E; Pucci P; Pollegioni L
FEBS J; 2016 Sep; 283(18):3353-70. PubMed ID: 27400736
[TBL] [Abstract][Full Text] [Related]
47. Serotonergic approaches in the development of novel antipsychotics.
Jones CA; McCreary AC
Neuropharmacology; 2008 Nov; 55(6):1056-65. PubMed ID: 18621404
[TBL] [Abstract][Full Text] [Related]
48. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus.
Uslaner JM; Parmentier-Batteur S; Flick RB; Surles NO; Lam JS; McNaughton CH; Jacobson MA; Hutson PH
Neuropharmacology; 2009; 57(5-6):531-8. PubMed ID: 19627999
[TBL] [Abstract][Full Text] [Related]
49. The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors.
Smith SM; Uslaner JM; Hutson PH
Open Med Chem J; 2010 May; 4():3-9. PubMed ID: 20648222
[TBL] [Abstract][Full Text] [Related]
50. DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study.
Jönsson EG; Saetre P; Vares M; Andreou D; Larsson K; Timm S; Rasmussen HB; Djurovic S; Melle I; Andreassen OA; Agartz I; Werge T; Hall H; Terenius L
Neuropsychobiology; 2009; 59(3):142-50. PubMed ID: 19439994
[TBL] [Abstract][Full Text] [Related]
51. Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia.
Fradley R; Goetghebeur P; Miller D; Burley R; Almond S; Gruart I Massó A; Delgado García JM; Zhu B; Howley E; Neill JC; Grayson B; Gaskin P; Carlton M; Gray I; Serrats J; Davies CH
Neurochem Res; 2023 Oct; 48(10):3027-3041. PubMed ID: 37289348
[TBL] [Abstract][Full Text] [Related]
52. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
Millan MJ; Brocco M
Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
[TBL] [Abstract][Full Text] [Related]
53. Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant.
Lin CH; Chen YM; Lane HY
Curr Drug Targets; 2020; 21(6):610-615. PubMed ID: 31660823
[TBL] [Abstract][Full Text] [Related]
54. D-Amino-Acid Oxidase Inhibition Increases D-Serine Plasma Levels in Mouse But not in Monkey or Dog.
Rojas C; Alt J; Ator NA; Thomas AG; Wu Y; Hin N; Wozniak K; Ferraris D; Rais R; Tsukamoto T; Slusher BS
Neuropsychopharmacology; 2016 May; 41(6):1610-9. PubMed ID: 26471255
[TBL] [Abstract][Full Text] [Related]
55. The chakragati mouse: a mouse model for rapid in vivo screening of antipsychotic drug candidates.
Dawe GS; Ratty AK
Biotechnol J; 2007 Nov; 2(11):1344-52. PubMed ID: 17886239
[TBL] [Abstract][Full Text] [Related]
56. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
Bridges TM; Williams R; Lindsley CW
Curr Opin Mol Ther; 2008 Dec; 10(6):591-601. PubMed ID: 19051137
[TBL] [Abstract][Full Text] [Related]
57. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
58. Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors.
Szilágyi B; Kovács P; Ferenczy GG; Rácz A; Németh K; Visy J; Szabó P; Ilas J; Balogh GT; Monostory K; Vincze I; Tábi T; Szökő É; Keserű GM
Bioorg Med Chem; 2018 May; 26(8):1579-1587. PubMed ID: 29472125
[TBL] [Abstract][Full Text] [Related]
59. Determination of D-serine and D-alanine Tissue Levels in the Prefrontal Cortex and Hippocampus of Rats After a Single Dose of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, with Potential Antipsychotic and Antidepressant Properties.
Huang CC; Wei IH; Yang HT; Lane HY
Neurochem Res; 2023 Jul; 48(7):2066-2076. PubMed ID: 36786942
[TBL] [Abstract][Full Text] [Related]
60. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
